Evidence map›Paper›PMID 41532766›Full record

ArticleAntimicrobial agents and chemotherapy2026

Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls

Hilliard L Kutscher, Maria Tamblin, Evon Smith, Arnav Shah, Patrick O Kenney, Jessica L Reynolds

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hilliard L Kutscher *Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0003-4779-2132
Maria Tamblin *Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
Evon SmithDivision of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
Arnav ShahDivision of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
Patrick O KenneyAdult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0003-0410-5224
Jessica L ReynoldsDivision of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-5188-6786

Funding

Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeuticnanoparticles for TBR01AI129649 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2018 to 2022
$2.2M
Immunotherapeutic nanoparticles: Implications for the treatment of tuberculosis and HIVR21AI179228 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2023 to 2024
$442k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases R01AI129649Division of Intramural Research, National Institute of Allergy and Infectious Diseases R21AI179228NIAID NIH HHS R01 AI129649NIAID NIH HHS R21 AI179228
6 · The paper itself

Abstract

To address limitations in tuberculosis (TB) therapy, we developed an inhalable, immunomodulating, biocompatible nanoparticle system (β-C-P) encapsulating rifampin that targets alveolar macrophage. The nanoparticle consists of a poly(lactic-co-glycolic acid) (PLGA) core, a chitosan coating, and a surface functionalized with 1,3-β-glucan for enhanced macrophage uptake and immunomodulation. We evaluated the safety, immunological effects, and efficacy of rifampin-loaded β-C-P nanoparticles delivered via oropharyngeal aspiration (OPA) in healthy mice and in a low-dose

Indexed as

beta-GlucansChitosanLactic AcidMycobacterium tuberculosisNanoparticlesPolyglycolic AcidRifampinAnimalsBronchoalveolar Lavage FluidFemaleLungMiceMice, Inbred BALB CPolylactic Acid-Polyglycolic Acid Copolymerbeta-GlucansChitosanLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRifampinbeta glucanimmune profilingMycobacterium tuberculosisnanoparticlesPLGArifampin

Identifiers

PMID41532766
PMCPMC12888923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.